Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: the French national AcSé Program

Congress : ASCO

Authors : Gilles Vassal, Nathalie Cozic, Gilbert Ferretti, Sophie Taïeb, Roch Houot, Laurence Brugières, Thomas Aparicio, Jean-Yves Blay, Ivan Bièche, Sylvie Lantuejoul, Céline Mahier – Ait Oukhatar, Natalie Hoog-Labouret, Denis Moro-Sibilot.l

Experts group or program : Médecine personnalisée


Crizotinib (czb) is only registered for treating ALK and ROS1-translocated lung cancer. However, Czb is also a MET inhibitor. Several malignancies are characterized by MET amplification (amp). Czb activity in MET-amplified (+) tumors was explored within the French National Cancer Institute (INCa) AcSé program. This included access to tumor molecular diagnoses and an exploratory multi-tumor 2-stage design phase II trial. We herein report the results in patients (pts) with esogastric MET+ adenocarcinomas (adenoK).

En savoir plus